BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hasan S, Abel S, Verma V, Webster P, Arscott WT, Wegner RE, Kirichenko A, Simone CB 2nd. Proton beam therapy versus stereotactic body radiotherapy for hepatocellular carcinoma: practice patterns, outcomes, and the effect of biologically effective dose escalation. J Gastrointest Oncol 2019;10:999-1009. [PMID: 31602338 DOI: 10.21037/jgo.2019.08.03] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Chu SS, Kuo YH, Liu WS, Wang SC, Ho CH, Chen YC, Yang CC, Wu HC. Effect of radiotherapy on survival in advanced hepatocellular carcinoma patients treated with sorafenib: a nationwide cancer-registry-based study. Sci Rep 2021;11:1614. [PMID: 33452421 DOI: 10.1038/s41598-021-81176-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
2 Cozzi L, Comito T, Loi M, Fogliata A, Franzese C, Franceschini D, Clerici E, Reggiori G, Tomatis S, Scorsetti M. The Potential Role of Intensity-Modulated Proton Therapy in Hepatic Carcinoma in Mitigating the Risk of Dose De-Escalation. Technol Cancer Res Treat 2020;19:1533033820980412. [PMID: 33287650 DOI: 10.1177/1533033820980412] [Reference Citation Analysis]
3 Garg T, Shrigiriwar A, Habibollahi P, Cristescu M, Liddell RP, Chapiro J, Inglis P, Camacho JC, Nezami N. Intraarterial Therapies for the Management of Hepatocellular Carcinoma. Cancers (Basel) 2022;14:3351. [PMID: 35884412 DOI: 10.3390/cancers14143351] [Reference Citation Analysis]
4 Uchinami Y, Katoh N, Suzuki R, Kanehira T, Tamura M, Takao S, Matsuura T, Miyamoto N, Fujita Y, Koizumi F, Taguchi H, Yasuda K, Nishioka K, Yokota I, Kobashi K, Aoyama H. A study on predicting cases that would benefit from proton beam therapy in primary liver tumors of less than or equal to 5 cm based on the estimated incidence of hepatic toxicity. Clinical and Translational Radiation Oncology 2022;35:70-5. [DOI: 10.1016/j.ctro.2022.05.004] [Reference Citation Analysis]
5 Tsai YL, Takei H, Iizumi T, Okumura T, Sekino Y, Numajiri H, Ishikawa H, Sakae T, Sakurai H. Capacity of proton beams in preserving normal liver tissue during proton beam therapy for hepatocellular carcinoma. J Radiat Res 2021;62:133-41. [PMID: 33392617 DOI: 10.1093/jrr/rraa098] [Reference Citation Analysis]
6 Roberts HJ, Wo JY. Stereotactic body radiation therapy for primary liver tumors: An effective liver-directed therapy in the toolbox. Cancer 2021. [PMID: 34847255 DOI: 10.1002/cncr.34033] [Reference Citation Analysis]
7 Siddiqui O, Pollock A, Samanta S, Kaiser A, Molitoris JK. Proton Beam Therapy in Liver Malignancies. Curr Oncol Rep 2020;22:30. [PMID: 32108284 DOI: 10.1007/s11912-020-0889-9] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Kumari S, Mukherjee S, Sinha D, Abdisalaam S, Krishnan S, Asaithamby A. Immunomodulatory Effects of Radiotherapy. Int J Mol Sci 2020;21:E8151. [PMID: 33142765 DOI: 10.3390/ijms21218151] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
9 Simone CB 2nd, Plastaras JP, Jabbour SK, Lee A, Lee NY, Choi JI, Frank SJ, Chang JY, Bradley J. Proton Reirradiation: Expert Recommendations for Reducing Toxicities and Offering New Chances of Cure in Patients With Challenging Recurrence Malignancies. Semin Radiat Oncol 2020;30:253-61. [PMID: 32503791 DOI: 10.1016/j.semradonc.2020.02.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
10 Chow R, Simone CB 2nd, Jairam MP, Swaminath A, Boldt G, Lock M. Radiofrequency ablation vs radiation therapy vs transarterial chemoembolization vs yttrium 90 for local treatment of liver cancer - a systematic review and network meta-analysis of survival data. Acta Oncol 2022;61:484-94. [PMID: 34846988 DOI: 10.1080/0284186X.2021.2009563] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
11 Bhangoo RS, Mullikin TC, Ashman JB, Cheng TW, Golafshar MA, DeWees TA, Johnson JE, Shiraishi S, Liu W, Hu Y, Merrell KW, Haddock MG, Krishnan S, Rule WG, Sio TT, Hallemeier CL. Intensity Modulated Proton Therapy for Hepatocellular Carcinoma: Initial Clinical Experience. Adv Radiat Oncol 2021;6:100675. [PMID: 34409199 DOI: 10.1016/j.adro.2021.100675] [Reference Citation Analysis]
12 Kobeissi JM, Hilal L, Simone CB 2nd, Lin H, Crane CH, Hajj C. Proton Therapy in the Management of Hepatocellular Carcinoma. Cancers (Basel) 2022;14:2900. [PMID: 35740567 DOI: 10.3390/cancers14122900] [Reference Citation Analysis]
13 Tong VJW, Shelat VG, Chao YK. Clinical application of advances and innovation in radiation treatment of hepatocellular carcinoma. J Clin Transl Res 2021;7:811-33. [PMID: 34988334] [Reference Citation Analysis]
14 Kim TH, Park JW, Kim BH, Oh ES, Youn SH, Moon SH, Kim SS, Woo SM, Koh YH, Lee WJ, Kim DY. Phase II Study of Hypofractionated Proton Beam Therapy for Hepatocellular Carcinoma. Front Oncol 2020;10:542. [PMID: 32411594 DOI: 10.3389/fonc.2020.00542] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
15 Simone CB 2nd. First Randomized Trial Supporting the Use of Proton Over Photon Chemoradiotherapy in Esophageal Cancer. J Clin Oncol 2020;38:2952-5. [PMID: 32706638 DOI: 10.1200/JCO.20.01405] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
16 Dionisi F, Brolese A, Siniscalchi B, Giacomelli I, Fracchiolla F, Righetto R, Morganti AG, Pravadelli C, Avancini I, Rozzanigo U, Mattiuzzi A, Frisinghelli M, Pertile R, Ciarleglio FA, Vitale A, Schwarz M, Amichetti M. Clinical results of active scanning proton therapy for primary liver tumors. Tumori 2021;107:71-9. [PMID: 32648818 DOI: 10.1177/0300891620937809] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
17 Maillie L, Lazarev S, Simone CB 2nd, Sisk M. Geospatial Disparities in Access to Proton Therapy in the Continental United States. Cancer Invest 2021;39:582-8. [PMID: 34152235 DOI: 10.1080/07357907.2021.1944180] [Reference Citation Analysis]
18 Wei S, Lin H, Choi JI, Press RH, Lazarev S, Kabarriti R, Hajj C, Hasan S, Chhabra AM, Simone CB 2nd, Kang M. FLASH Radiotherapy Using Single-Energy Proton PBS Transmission Beams for Hypofractionation Liver Cancer: Dose and Dose Rate Quantification. Front Oncol 2021;11:813063. [PMID: 35096620 DOI: 10.3389/fonc.2021.813063] [Reference Citation Analysis]